Exploring the importance of contract development and manufacturing organizations in advancing the latest technology for effective delivery of temperature-sensitive medicines.

In the second part of his video interview with Pharma Commerce Editor Nicholas Saraceno, Chris O’Dell, Turquoise Health’s SVP of market solutions, discusses the biggest challenges healthcare organizations currently face in terms of price transparency.

Steffen Lang, president, operations, executive committee member, Novartis, discusses what to expect from Novartis over the next decade in terms of technological innovations.

The key strategies for reducing or eliminating post-prescription abandonment.

Why taking proactive steps—and combing the right data sources—is critical to informed decision-making in risk management.

Steffen Lang, president, operations, executive committee member, Novartis, discusses how technology will continue to enhance operations and how it will impact patients.

In the final part of her video interview with Pharma Commerce Editor Nicholas Saraceno, Kimberly Westrich, chief strategy officer at the National Pharmaceutical Council, comments on another presentation that has caught her eye at the conference.

The latest news for pharma industry insiders.

A look at the prevailing factors impacting treatment access in 2025.

How pharma manufacturers can steadily navigate GTN components and complexities when planning pharmacy benefit reimbursement.

Steffen Lang, president, operations, executive committee member, Novartis, shares strategic insights on how pharma supply chain leaders can elevate operations to drive innovation, growth, and patient impact.

In the third part of her video interview with Pharma Commerce Editor Nicholas Saraceno, Kimberly Westrich, chief strategy officer at the National Pharmaceutical Council, details the aspect of her presentation that she would have wanted to dive further into.

The latest news for pharma industry insiders.

How can stakeholders prepare for changing therapy requirements?

Respective industry and government agendas could significantly reshape the US prescription drug market.

Ensuring that essential treatments reach patients safely and efficiently is an increasing imperative in today's pharma landscape.

A keynote presentation describes how supply chain visibility should rely on digital capabilities.

Steffen Lang, president, operations, executive committee member, Novartis, discusses the premise of a keynote session on reimagining operations.

In the final part of his video interview with Pharma Commerce Editor Nicholas Saraceno, Colin Banas, MD, DrFirst’s chief medical officer, shares his thoughts on the rumors that RFK Jr. could potentially ban DTC advertising.

In the first part of his video interview with Pharma Commerce Editor Nicholas Saraceno, Chris O’Dell, Turquoise Health’s SVP of market solutions, outlines the key provisions of the recently released executive order on healthcare price transparency.

The latest news for pharma industry insiders.

A panel discussion breaks down ways for stakeholders to meet temperature-controlled operational demands pertaining to product pipelines.

How data-driven insights can help pharma companies balance their revenue management and innovation strategies—including resource allocation, pricing, and market access.

Taking stock of today's gains and tomorrow's potential for generative artificial intelligence in reshaping the industry.